Overview

Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer

Status:
Active, not recruiting

Trial end date:
2022-07-31

Target enrollment:

Participant gender:

Summary

JTX-2011-201 is a Phase 2, open label clinical study of vopratelimab (JTX-2011) and ipilimumab in adult subjects with non-small cell lung cancer (NSCLC) or urothelial cancer to evaluate safety and efficacy.

Phase:

Phase 2

Details

Lead Sponsor:

Jounce Therapeutics, Inc.

Treatments:

Antibodies, Monoclonal
Ipilimumab